HLB is taking control of changes of the future in various business fields, with
constant efforts and passion.
HLB’s Chairman Yangon Jin declares “will put every effort into bio biz to jump to a global firm”
Chairman Yangon announced that HLB is going to jump to a global bio firm, creating innovations through bio industry which grows rapidly with its technical evolution.
In his greetings for HLB’s “Bio Business and Beyond”, held in JW Marriott hotel, Kangnam, Seoul, the chairman Yangon spoke about paths and innovations that HLB has been taking with.
“HLB has been running shipbuilding business over last 40 years, and paid attention to bio industry as a continuous innovation. Though there have been many difficulties as a small-midsized company, the company has been developing Bioartificial Liver & target cancer therapy for years and now it entered to a point to expect visible results”, he said.
He added, “it’s going to be a big contribution to both industry and the nation if the investment on the Bioartificial Liver and target cancer therapy bears fruit”, “HLB has raised importance of the bio business, and the future strategy will also be aggressive to it.”
Especially, he emphasized the importance of a leader, “I strongly agree that a firm goes off with its CEO. Thus, I think that CEO has to put all of him and has a huge responsibility in it.”
HLB, the lifeboat and marine composite material firm, has been investing two bio companies, the Bioartificial Liver from 1998, and LSKB from 2005
The forum went with LSKB and core board members of Bioartificial Liver Company, researchers of immunosuppressant and medical scientists involved in bio business, who had discussions on the results of the clinical experiments and future strategies, introduction of HLB’s subsidiary and its development plans.
The sessions were consisted of “Apatinib clinical experiment update”, “introduction of HLB’s pipelines”, and “development of new drug candidates forecast”. 100 participants attended and graced the spot were LSKB’s CEO Sungchul Kim, Md. Yunku Kang at Seoul Asan Hospital, analysts from security firms, and institutional investors.